Hikma Strikes Deal For Ryaltris In US
Agreement With Glenmark Builds On Nasal Spray Portfolio
Hikma has struck a deal with Glenmark to gain US rights to its Ryaltris nasal spray. The agreement comes as Hikma reported sales ahead by 7% in 2019 on strong performances from the firm’s Injectables and Branded segments.
You may also be interested in...
Glenmark is celebrating the approval of its Ryaltris nasal spray in 13 European countries, with the Indian company and partner Menarini set to begin rolling out the allergic rhinitis combination product.
Business development must be treated as a “strategic tool,” with partnerships and acquisitions selected based on how they fit into the company’s bigger picture, Hikma’s newly-appointed vice-president of business development for generics Patrick Genestin tells Generics Bulletin in an exclusive interview.
Glenmark has struck the latest in a series of commercialization deals for its Ryaltris nasal spray in the form of a ten-year alliance with Bausch Health for the Canadian market.